[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto de Investigación Marqués de Valdecilla\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":279},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,86,116,143,166,191,220,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100638937","phase-4-carotid-ultrasound-based-strategy-for-primary-prevention-of-cardiovascular-events-in-inflammatory-rheumatic-disease-prevener-100638937",false,"NCT07611747","Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)","Randomized Clinical Trial to Assess the Efficacy and Safety of a Primary Prevention Strategy for Cardiovascular Events in Patients With Inflammatory Rheumatic Diseases Based on the Use of Carotid Ultrasound","PREVENER","Inclusion Criteria:\n\n1. Patients aged ≥50 years who have provided written informed consent.\n2. Fulfillment of classification criteria for at least one of the following inflammatory rheumatic diseases:\n\n   * Rheumatoid arthritis (RA) according to ACR\u002FEULAR 2010 criteria\n   * Psoriatic arthritis (PsA) according to CASPAR criteria\n   * Axial spondyloarthritis (AxSpA) according to ASAS criteria\n   * Systemic lupus erythematosus (SLE) according to ACR\u002FEULAR 2019 criteria\n3. Low-to-moderate cardiovascular risk according to SCORE2\u002FOP classification.\n\nExclusion Criteria:\n\n1. Presence of previous cardiovascular events, type 2 diabetes mellitus, familial hypercholesterolemia, or chronic kidney disease resulting in classification as high or very high cardiovascular risk.\n2. Prior carotid ultrasound examination with subsequent therapeutic intervention derived from its results, either in the context of a research study or routine clinical practice.\n3. Contraindications to lipid-lowering therapy, including recent history of alcoholism, active liver disease, or unexplained and persistent elevation of serum transaminases exceeding three times the upper limit of normal (applicable to statins and ezetimibe).","ALL","50 Years",{"count":20,"type":21},1944,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases (IRD).\n\nPatients with IRD, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and systemic lupus erythematosus (SLE), have a 50% higher risk of cardiovascular (CV) events compared to the general population. However, conventional CV risk scores (SCORE2\u002FOP) systematically underestimate this risk, leaving many high-risk patients without appropriate preventive treatment.\n\nPatients aged ≥50 years with IRD and low-to-moderate CV risk according to SCORE2\u002FOP will be randomized 1:1 to either an experimental group (carotid ultrasound to detect subclinical atherosclerosis) or a control group (standard care according to ESC 2021 guidelines). Patients in the experimental group with carotid plaques will be reclassified as very high CV risk and treated with high-intensity statins (LDL target \\\u003C55 mg\u002FdL). The primary endpoint is the incidence of major adverse cardiovascular events (MACE) over 48 months of follow-up.",[27,28,29,30,31,32,33],"Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)","Axial Spondy","Systemic Lupus Erythematosus (SLE)","Caridovascular Disease","Atherosclerosis","Carotid Artery Diseases",[35,36,37,38,39],"Carotid ultrasound","Carotid plaques","Subclinical atherosclerosis","Cardiovascular prevention","Inflammatory rheumatic diseases","RECRUITING","2026-05-20",{"date":43,"type":44},"2026-05-28","ACTUAL",{"date":46,"type":44},"2026-04-22",{"date":48,"type":21},"2031-12",{"name":50,"class":51},"Instituto de Investigación Marqués de Valdecilla","OTHER",17,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100640568","evaluation-of-balloon-guide-catheter-as-proximal-protection-during-carotid-artery-stenting-embo-protect-100640568","NCT07576790","Evaluation of Balloon Guide Catheter as Proximal Protection During Carotid Artery Stenting (EMBO-PROTECT)","Evaluation of Balloon Guide Catheter as Proximal Protection During Carotid Artery Stenting: A Randomized Study (EMBO-PROTECT)","EMBO-PROTECT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Symptomatic or asymptomatic carotid artery stenosis\n* Candidate for carotid artery stenting\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Vascular anatomy unsuitable for balloon guide catheter placement\n* Severe renal failure\n* Previous disabling stroke or symptomatic intracranial hemorrhage\n* Evidence of carotid thrombus\n* Severe common carotid artery lesion\n* Chronic atrial fibrillation on oral anticoagulation\n* Acute coronary syndrome within 30 days\n* Contraindications to anticoagulant or antiplatelet therapy\n* Contraindications to MRI\n* Contrast media allergy\n* Lack of prior dual antiplatelet therapy","18 Years",{"count":63,"type":21},126,[65],"NA","Carotid angioplasty and stenting (CAS) is an effective treatment for carotid artery stenosis but carries a risk of cerebral embolization. This prospective randomized study evaluates the safety and efficacy of proximal embolic protection using a balloon guide catheter during CAS by comparing the incidence of diffusion-weighted MRI-detected microembolisms and symptomatic thromboembolic events between protected and unprotected procedures.",[68],"Carotid Artery Stenosis (Symptomatic and Asymptomatic)",[70,71,72,73,74,75,76],"Carotid stenosis","Carotid artery stenting","Balloon guide catheter","Proximal embolic protection","Cerebral microembolism","Diffusion-weighted MRI","Stroke prevention","NOT_YET_RECRUITING","2026-05-04",{"date":80,"type":44},"2026-05-08",{"date":82,"type":21},"2026-07-01",{"date":84,"type":21},"2027-12-31",{"name":50,"class":51},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100601645","randomized-a-clinical-trial-with-medical-device-in-acute-ischemic-stroke-100601645","NCT07113184","Randomized a Clinical Trial With Medical Device in Acute Ischemic Stroke","DUAL VERSUS SINGLE STENTRIEVER FOR RECANALIZATION IN ACUTE ISCHEMIC STROKE: THE RANDOMIZED DOUBLE UP TRIAL","DOBLE UP","Inclusion Criteria:\n\n* Age ≥ 18\n* NIHSS ≥ 6\n* mRS ≤ 1\n* Proximal anterior circulation occlusion\n* ASPECTS \\> 6\n* Informed consent\n\nExclusion Criteria:\n\n* Absence of occlusion\n* Posterior circulation stroke\n* Carotid dissection or tandem stenosis requiring treatment\n* Severe comorbidities or contraindications to imaging contrast",{"count":95,"type":21},220,[65],"This study seeks to provide high-quality evidence on the potential benefits of the dual stentriever approach, potentially informing future clinical guidelines and improving outcomes in patients with anterior circulation large vessel occlusion strokes.",[99],"Acute Ischemic Stroke",[101,102,103,104,105,106],"Acute ischemic stroke","mechanical thrombectomy","dual stentriever","mTICI","first pass effect","randomized trial","2025-08-04",{"date":109,"type":44},"2025-08-08",{"date":111,"type":21},"2025-10-01",{"date":113,"type":21},"2026-12-31",{"name":50,"class":51},3,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100585931","utility-of-rotem-for-risk-stratification-of-post-invasive-procedure-hemorrhage-in-patients-with-cirrhosis-cir-rotem-100585931","NCT06908785","Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM)","CIR-ROTEM","Inclusion Criteria:\n\n* Age between 18 and 85 years.\n* Clinical, analytical, elastographic, histological, and\u002For imaging criteria consistent with the diagnosis of hepatic cirrhosis.\n* Undergoing a high-risk invasive procedure, either in an outpatient setting or during hospitalization.\n* Platelet count below 50,000\u002FμL or INR greater than 1.5 with a platelet count below 100,000\u002FμL.\n* Signature of informed consent.\n\nExclusion Criteria:\n\n* Cirrhotic patients with acute-on-chronic liver failure (ACLF) as defined by EASL criteria, and patients admitted to Intensive Care Units. These patients are excluded because hemostatic alterations in ACLF and critically ill patients are different and more pronounced compared to those in outpatient or general medical ward settings.\n* Chronic kidney disease stage ≥3.\n* Presence and\u002For history of thromboembolic complications.\n* Presence of non-hepatic tumors.\n* Presence of any primary hematologic disease (including inherited coagulopathies or thrombophilia).\n* Recent surgery (\\\u003C8 weeks).\n* History of organ transplantation, including liver transplantation.\n* Pregnancy.\n* Use of anticoagulants, antiplatelet agents other than acetylsalicylic acid, and\u002For antifibrinolytic therapy.\n* Active disseminated intravascular coagulation.","65 Years",{"count":125,"type":21},330,"OBSERVATIONAL","The assessment of post-procedural bleeding risk in cirrhosis remains a clinical challenge due to the lack of precise predictive tools and its high associated mortality. Although guidelines recommend a restrictive transfusion policy, adherence remains low, with a high rate of prophylactic transfusions despite unclear benefits. This multicenter, prospective, and observational study will evaluate the utility of ROTEM in bleeding risk stratification for cirrhotic patients with significant abnormalities in conventional hemostasis tests undergoing high-risk invasive procedures. The primary objective is to establish cut-off values with a high negative predictive value, optimizing transfusion decisions and reducing unnecessary blood product use. Additionally, the study will analyze the relationship between ROTEM, inflammation biomarkers, and coagulation factors, along with a cost-effectiveness analysis comparing different transfusion strategies. This will be the largest study to date assessing ROTEM in this setting, overcoming the limitations of previous studies, which have been mostly retrospective with heterogeneous populations and procedures. Its findings could contribute to the standardization of transfusion management in cirrhosis and improve healthcare resource efficiency. The widespread availability of ROTEM in other disciplines within the National Health System will facilitate its implementation in this clinical setting without requiring additional investment in equipment.",[129],"Cirrhosis, Liver",[131,132,133],"Hemorrhage","Viscoelastic tests","Rotational thromboelastometry","2025-04-02",{"date":136,"type":44},"2025-04-03",{"date":138,"type":44},"2025-03-01",{"date":140,"type":21},"2028-09-01",{"name":50,"class":51},11,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100573999","effectiveness-of-an-act-based-cognitive-intervention-on-quality-of-life-and-cognitive-function-in-elderly-residents-with-mci-100573999","NCT06753578","Effectiveness of an ACT-Based Cognitive Intervention on Quality of Life and Cognitive Function in Elderly Residents With MCI","EACT","Inclusion Criteria:\n\n* Residents aged 65 and older diagnosed with MCI, able to provide informed consent, and residing in participating long-term care facilities.\n\nExclusion Criteria:\n\n* Individuals with severe cognitive impairment, unstable medical conditions, or psychiatric diagnoses that would interfere with participation.",{"count":151,"type":21},215,[65],"This study investigates the effects of an Acceptance and Commitment Therapy (ACT)-based cognitive intervention on Quality of Life (QOL) and cognitive function among elderly residents with Mild Cognitive Impairment (MCI) in long-term care settings. The study assesses immediate and long-term impacts on cognitive function, psychological flexibility, social engagement, and overall well-being through structured ACT-based training.",[155],"Mild Cognitive Impairment",[155],"2024-12-30",{"date":159,"type":44},"2024-12-31",{"date":161,"type":44},"2024-01-01",{"date":163,"type":21},"2025-06-01",{"name":50,"class":51},1,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":165},"100568495","phase-3-oropharyngeal-myofunctional-therapy-in-obstructive-sleep-apnea-100568495","NCT06681974","OROPHARYNGEAL MYOFUNCTIONAL THERAPY IN OBSTRUCTIVE SLEEP APNEA","RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL TO ANALYZE THE EFFECTIVENESS OF OROPHARYNGEAL MYOFUNCTIONAL THERAPY IN MILD-MODERATE OBSTRUCTIVE SLEEP APNEA IN THE GENERAL POPULATION","Inclusion Criteria:\n\n* Acceptance and signature of the informed consent\n* Diagnosis of OSA with mild-moderate AHI without criteria for treatment with CPAP and\u002For other treatments (DAM).\n* Patients who refused CPAP, were not candidates and\u002For refused DAM.\n* Age \\> 18 years and \\\u003C 70 years\n\nExclusion Criteria:\n\n* Craniofacial malformations. Severe developmental delay. Intellectual disability.\n* Diagnosis of neurodegenerative disease.\n* Limited tongue mobility\u002Fpresence of ankyloglossia as well as Temporo-Mandibular Joint pathology.\n* Regular use of hypnotic medications\n* Bulbar pathologies\n* AHI of central origin above 50% of the total sleep time.\n* Obesity grade II or more.\n* Severe cardiovascular, neuromuscular or pulmonary pathology or chronic domiciliary oxygen use. Hypoventilation-obesity syndrome.\n* Refuse to participate in the clinical trial despite fulfilling the inclusion criteria and not presenting any exclusion criteria.","70 Years",{"count":175,"type":21},30,[177],"PHASE3","Obstructive Sleep Apnea (OSA) is a prevalent nocturnal breathing disorder among the general population. Oropharyngeal myofunctional therapy (OMT) is an alternative conservative treatment used to improve OSA, associated health problems, and to improve the efficacy and tolerability of CPAP.\n\nThe objective is to determine the effect of OMT in the general population with mild-moderate OSA.\n\nThe overall study design will be a randomized controlled clinical trial with parallel groups. Both the control group and the intervention group will receive the same indications on the hygienic-dietary measures to be followed. The intervention group will also follow an exercise program based on OMT for 20 weeks. The effect on the apnea-hypopnea index and other variables will be determined by means of respiratory polygraphy before and after the intervention.",[180],"Obstructive Sleep Apnea",[182,180],"Oropharyngeal myofunctional therapy","2024-11-12",{"date":185,"type":44},"2024-11-14",{"date":187,"type":44},"2023-05-01",{"date":189,"type":21},"2024-12-01",{"name":50,"class":51},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100563369","pressure-injuries-in-the-operating-room-and-their-perioperative-incidence-in-patients-undergoing-neurosurgery-100563369","NCT06615271","Pressure Injuries in the Operating Room and Their Perioperative Incidence in Patients Undergoing Neurosurgery.","UPS","Inclusion Criteria:\n\n* Patients who understand and sign the informed consent.\n* Adult patients of both sexes who will undergo a schedule surgery of more than 3 hours, by the service of neurosurgery of the University Hospital Marqués of Valdecilla (HUMV), between 2023 and 2024.\n* Patients positioned in prone, supine, lateral and beach chair\u002Fsitting.\n* Surgeries susceptible to bladder catheterisation with body temperature measurement.\n* Patients admitted into neurosurgery ward, the day before surgery.\n\nExclusion Criteria:\n\n* Patients who do not sign informed consent.\n* Patients with visible pressure injurie present before surgery.\n* Patients with cognitive disorder or written and oral knowledge difficulty.\n* Patients who reject the operation.\n* Patients not operated due to lack of prior time.\n* Patients who do not receive vasoactive drugs such as ephedrine, phenylephrine and noradrenaline.\n* Patients whose postoperative period is performed in the ICU.\n* Patients whose surgical intervention, despite the initial estimate of the surgical time, lasted less than 3 hours.\n* Patients admitted \\>24 hours prior the surgery.","100 Years",{"count":200,"type":21},170,"This research project is a descriptive, longitudinal prospective observational study in the HUMV neurosurgery operating rooms. The patients included will be adults 18 years old or older, who will be scheduled for surgery by the Neurosurgery service. Those who meet the selection criteria determined for this study will be chosen consecutively and will be followed from the immediate preoperative moment until 72 hours after the end of the surgery. Data collection shall be carried out by direct observation and immersion in clinical records of patients who have signed the informed consent. The study will be carried out in 4 phases: immediate preoperative, intraoperative, immediate postoperative and late postoperative, recording the data using various measuring instruments, and a record sheet. Finally, the cumulative incidence of LPPs developed in the perioperative environment will be calculated and a statistical analysis will be performed.",[203],"PRESSURE INJURIES",[205,206,207,208,209,210],"injuries","surgical","neurosurgery","prevention","nurse","clinical practice","2024-09-24",{"date":213,"type":44},"2024-09-26",{"date":215,"type":44},"2023-12-01",{"date":217,"type":21},"2025-01-01",{"name":50,"class":51},2,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":165},"100366843","phase-2-prophylaxis-of-cytomegalovirus-infection-with-adoptive-cell-inmunotherapy-100366843","NCT04056533","Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy","Anti-CMV Pilot Clinical Trial: Prophylaxis of Cytomegalovirus Infection in Haploidentical Transplatation of Hematopoietic Progenitors With Adoptive Cell Inmunotherapy","INMUNOCELL","Inclusion Criteria:\n\n* Adult patients who received an alogeneic stem cell transplantation from haploidentical donors (HAPLO).\n* Any source of stem cells (peripheral blood or bone marrow).\n* CMV-seropositive donors.\n* Negative pregnancy test in women.\n* Signed writen informed consent.\n* DONORS:\n\n  1. HLA haploidentical and CMV-seropositve donors.\n  2. Donor must be checked and suitable.\n  3. Signed writen informed consent.\n  4. Donor without active infection evidence at leukapheresis.\n\nExclusion Criteria:\n\n* Patients without haploidentical CMV-seropositive donors.\n* Patients who are not suitable for follow up visits.\n\nCMV-CTLs Infusion Criteria:\n\n* Hematopoiesis recovery at least partial (neutrophil counts \\>0.5x10\\^9\u002FL in at least 3 consecutive samples post-transplant).\n\nCMV-CTLs NON-Infusion Criteria:\n\n* Patients receiving corticosteroid (dose of 0.5mg\u002Fkg\u002Fday of prednisone or equivalent) at infusion.\n* ECOG \\> or = 3.\n* Organic toxicities grade \\> or = 3.\n* Patients who received ATG, donor lymphocytes or alemtuzuamb, 28 days pre-infusion.\n* Patients with uncontroled infection defined by fevers and\u002For inestability and\u002For infection not resolved.\n* Persistent fevers 3 days before infusion.\n* Acute Graft Versus Host Disease (GVHD) grade II-IV.\n* Relapse or progression after transplant and before infusion day.\n* CMV reactivation\u002Finfection after transplant and before infusion day.\n\nPatients who don´t fill infusion criteria, after day 28 post-HAPLO, will be considered screening failures and will be out of the study.","80 Years",{"count":230,"type":21},15,[232],"PHASE2","Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). Recently, strategies based on immunotherapy adoptive cells (IAC) with anti-CMV Cytolitic T Lymphocytes (CMV-CTLs) has been incorporated to prevent or treat CMV after HSCT. The aim to study donor derived CMV-CTLs after haploidentical HSCT (HAPLO) as prophylaxis for CMV infection in transplant patients. CMV-CTLs will be administer at day 21 (+-7 days) post-HAPLO. CMV DNA levels with quantitative PCR will be weekly monitored.",[235],"CMV",[237,238,239],"Citomegalovirus","Haploidentical","Hematopoietic Stem Cell Transplantation","2024-08-27",{"date":242,"type":44},"2024-08-28",{"date":244,"type":44},"2022-03-26",{"date":246,"type":21},"2026-12-01",{"name":50,"class":51},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":256,"sex":17,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":165},"100504772","a-population-based-cohort-in-northern-spain-100504772","NCT05852678","A Population-based Cohort in Northern Spain","The Cantabria Cohort, a Protocol for a Population-based Cohort in Northern Spain","COHORTE","Inclusion Criteria:\n\n* Participants between 40-69 years of age\n* Participants who sign the informed consent form\n* Participants legally residing in Cantabria\n\nExclusion Criteria:\n\n* Participants under 40 years of age and over 69 years of age\n* Participants not signing the informed consent form\n* Participants not legally residing in Cantabria",true,"40 Years","69 Years",{"count":260,"type":21},22000,"Cantabria Cohort stems from a research and action initiative lead by researchers from Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital and University of Cantabria, supported by the regional Goverment. Its aim is to identify and follow up a cohort that would provide information to improve the understanding of the etiology and prognosis of different acute and chronic diseases. The Cantabria Cohort will recruit between 40,000-50,000 residents aged 40-69 years at baseline, representing 10-20% of the target population. Currently, more than 22,000 volunteers have been enrolled. All participants will be invited for a re-assessment every three years, while the overall duration is planned for twenty years. The repeated collection of biomaterials combined with broad information from participant questionnaires, medical examinations, actual health system records and other secondary public data sources is a major strength of its design, which will make it possible to address biological pathways of disease development, identify new factors involved in health and disease, design new strategies for disease prevention, and advance precision medicine. It is conceived to allow access to a large number of researchers worldwide to boost collaboration and medical research.",[263],"Chronic Disease",[265,266,267,268,269,270],"Lifestyle","Socio-economic factors","Biobank","Big data","Precision medicine","Longitudinal study","2023-05-11",{"date":273,"type":44},"2023-05-12",{"date":275,"type":44},"2021-04-20",{"date":277,"type":21},"2045-04-01",{"name":50,"class":51},""]